Placental function related to brain lesions related to autism (Representational Image) & nbsp Image credit: & nbspHinkstock
Washington DC: According to the developmental fetus, a hormone developed by alopregnanolone (ALLO) later on in pregnancy may discontinue cancer associated with autistic spectrum disorders (ASD) due to the uninterrupted developmental fetus. Research was presented at the Meeting of the Academy of Pediatric Society.
According to the Center for Disease Control and Prevention, about 10 babies are born about one month before pregnancy 37 weeks. Early birth is the main risk factor for ASD.
Placenta is a vital and understandable body that shares the fetus and pregnant mother's breast, delivers oxygen, glucose, and food, and extracts debris. Plazenta also provides a derivative of ALLO (progesterone), because fetal development needs to prepare the brain out of the stomach.
ALLO increases pregnancy during pregnancy. When babies are born early, ALLO supplies are interrupted. This happens at the same time as the cerebellum – a brain region that is crucial for coordination, posture, balance and social knowledge, usually has a huge growth.
"Our experimental model demonstrates that the loss of placental ALLO changes brain development, including the development of white people," said Dr. Anna Penn. neonatologist.
The research team created a new model where a gene that codifies the enzyme responsible for the production of ALLO placon's plates was eliminated. These preclinical models were compared with a control group and the two groups performed a complete brain image and the RNAseq gene expression.
"We saw changes in long-lasting brain matter in male experimental models, and behavioral studies increased social deterioration and recurring behavior, two distinctive characteristics of ASD, previously reported babies," said Claire-Marie Vacher, chief researcher.
"Our discoveries offer a new way of misunderstanding the placenta function: in the uterus they may have minor but significant changes in the development of neurodegenerative disorders that may later develop in children's lives," said Dr. Penn, senior author of the study.
"Future research may be the identification of new placenta or brain targets that could be appropriate for supplemental hormone, which will allow the treatment of high-risk fetuses," added Penn.